CSPC PHARMA's SYH2059 inhalation powder clinical trial approved by the US FDA

CSPC PHARMA (01093.HK) announced that the Group's developed chemical drug Class 1 new drug SYH2059 inhalation powder has been approved by the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the United States. The approved clinical indications include idiopathic pulmonary fibrosis and progressive pulmonary fibrosis